Clinical TrialMay 4, 2026, 07:07 AM
NextCure Initiates SIM0505 Dose Optimization for Ovarian Cancer
AI Summary
NextCure, Inc. and Simcere Zaiming Pharmaceutical Co., Ltd. announced the initiation of the dose optimization portion of the Phase 1 study for SIM0505, an investigational antibody drug conjugate. The study will initially focus on patients with platinum-resistant ovarian cancer, for which SIM0505 has received FDA Fast Track designation. NextCure plans to present Phase 1 data at the upcoming 2026 American Society of Clinical Oncology (ASCO) conference and is expanding trial sites globally.
Key Highlights
- NextCure initiated dose optimization for SIM0505 Phase 1 study.
- The study focuses on patients with platinum-resistant ovarian cancer (PROC).
- Phase 1 data readout for SIM0505 will be presented at ASCO 2026.
- SIM0505 is a novel CDH6-directed ADC with a topoisomerase 1 inhibitor payload.
- FDA granted Fast Track designation to SIM0505 for platinum-resistant ovarian cancer.
- Clinical trial sites are expanding to the U.S., China, Canada, and Europe.
Price Impact
More from NXTC